Challenges to genetic testing for germline mutations associated with breast cancer among African Americans Authors

被引:4
|
作者
Kamaraju, S. [1 ,2 ,3 ,4 ]
Conroy, M. [1 ,3 ]
Harris, A. [1 ,3 ]
Georgen, M. [1 ,2 ,3 ]
Min, H. [1 ,3 ]
Powell, M. [1 ,3 ]
Kurzrock, R. [1 ,2 ,3 ]
机构
[1] Med Coll Wisconsin, Milwaukee, WI USA
[2] Med Coll Wisconsin, Dept Med, Div Hematol Oncol, Milwaukee, WI USA
[3] Froedtert Hosp, Milwaukee, WI USA
[4] Med Coll Wisconsin, Canc Ctr, West Doyne Ave, Milwaukee, WI 53226 USA
关键词
African Americans; Germline mutations; Breast cancer; Social determinants of health; And cancer disparities; HEREDITARY BREAST; RISK-ASSESSMENT; INHERITED PREDISPOSITION; RACIAL-DIFFERENCES; RANDOMIZED-TRIAL; HEALTH LITERACY; OVARIAN-CANCER; BLACK-WOMEN; DISPARITIES; POPULATION;
D O I
10.1016/j.ctrv.2024.102695
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Inequities in preventive cancer screening, diagnosis, treatment, and inferior cancer outcomes continue to pose challenges across the cancer continuum. While the exact reasons for these inferior outcomes are unknown, multiple barriers to various domains of social determinants of health (SDOH) play a vital role, leading to inequities in cancer care. These include barriers to transportation, housing, and food insecurities, contributing to delays in preventive screening and treatment. Furthermore, aggressive biologies also exist across various racial profiles with accompanying germline mutations. For example, African Americans (AAs) have a higher incidence of triple -negative breast cancer subtype and a high prevalence of BRCA1/2 gene mutations, increasing the risk of multiple cancers, warranting high -risk screening for these populations. Unfortunately, other barriers, such as financial insecurities, low health literacy rates, and lack of awareness, lead to delays in cancer screening and genetic testing, even with available high -risk screening and risk reduction procedures. In addition, physicians receive minimal interdisciplinary training to address genetic assessment, interpretation of the results, and almost no additional training in addressing the unique needs of racial minorities, leading to suboptimal delivery of genetic assessment provision resources among AAs. In this review, we discuss the confluence of factors and barriers limiting genetic testing among AAs and highlight the prevalence of germline mutations associated with increased risk of breast cancer among AAs, reflecting the need for multi -panel germline testing as well as education regarding hereditary cancer risks in underserved minorities.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Germline RECQL gene mutations in Chinese patients with breast cancer
    Hu, Jun
    Shen, Yong
    Zhang, Kun
    Chen, Yiding
    FRONTIERS IN MEDICINE, 2024, 11
  • [42] Uptake of Risk-Reducing Measures, Cascade Testing, and Related Challenges Among Carriers of Breast Cancer-Associated Germline Pathogenic Variants in Mexico
    Mesa-Chavez, Fernanda
    Chavarri-Guerra, Yanin
    Aguilar-y-Mendez, Dione
    Becerril-Gaitan, Andrea
    Vaca-Cartagena, Bryan F.
    Carrillo-Bedoya, Araceli
    Santiesteban-Gonzalez, Salvador
    Aranda-Gutierrez, Alejandro
    Rodriguez-Faure, Andres
    Obregon-Leal, Daniela
    Quintero-Beulo, Gregorio
    Rodriguez-Olivares, Jose L.
    Miaja, Melina
    Weitzel, Jeffrey N.
    Villarreal-Garza, Cynthia
    JCO GLOBAL ONCOLOGY, 2024, 10
  • [43] Familial lobular breast cancer: Is testing for germline CDH1 mutations necessary?
    Corso, Giovanni
    Sacchini, Virgilio
    Pravettoni, Gabriella
    Veronesi, Paolo
    Bonanni, Bernardo
    EJSO, 2019, 45 (10): : 1760 - 1761
  • [44] Novel germline mutations in BRCA2 gene among 96 hereditary breast and breast–ovarian cancer families from Kerala, South India
    Vani Syamala
    Leelakumari Sreeja
    Volga S. Syamala
    B. Vinodkumar
    Praveenkumar B. Raveendran
    Hariharan Sreedharan
    Ratheesan Kuttappan
    Lekshmi Balakrishnan
    Ravindran Ankathil
    Journal of Cancer Research and Clinical Oncology, 2007, 133 : 867 - 874
  • [45] Integration of Universal Germline Genetic Testing for All New Breast Cancer Patients
    Culver, Julie O.
    Freiberg, Yael
    Ricker, Charite
    Comeaux, Jacob G.
    Chang, Emmeline Y.
    Banerjee, Victoria
    Sturgeon, Duveen
    Solomon, Ilana
    Kagey, Josie
    Dobre, Mariana G.
    Carey, Joseph
    Carr, Azadeh
    Cho, Stephanie
    Lu, Janice
    Kang, Irene M.
    Patel, Ketan
    Terando, Alicia
    Ye, Jason C.
    Li, Ming
    Lerman, Caryn
    Spicer, Darcy
    Nelson, Maria
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (02) : 1017 - 1025
  • [46] Access disparities and underutilization of germline genetic testing in Chilean breast cancer patients
    Francisco Acevedo
    Benjamín Walbaum
    Mauricio Camus
    Manuel Manzor
    Sabrina Muñiz
    Lidia Medina
    Militza Petric
    Paula Reyes
    Francisco Domínguez
    Klaus Puschel
    Tomas Merino
    M. Loreto Bravo
    Mauricio P. Pinto
    Carolina Ibáñez
    Kevin Hughes
    César Sánchez
    Breast Cancer Research and Treatment, 2023, 199 : 363 - 370
  • [47] BARRIERS TO GENETIC TESTING FOR BREAST CANCER RISK AMONG ETHNIC MINORITY WOMEN: AN EXPLORATORY STUDY
    Glenn, Beth A.
    Chawla, Neetu
    Bastani, Roshan
    ETHNICITY & DISEASE, 2012, 22 (03) : 267 - 273
  • [48] Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer
    Kleiblova, Petra
    Stolarova, Lenka
    Krizova, Katerina
    Lhota, Filip
    Hojny, Jan
    Zemankova, Petra
    Havranek, Ondrej
    Vocka, Michal
    Cerna, Marta
    Lhotova, Klara
    Borecka, Marianna
    Janatova, Marketa
    Soukupova, Jana
    Sevcik, Jan
    Zimovjanova, Martina
    Kotlas, Jaroslav
    Panczak, Ales
    Vesela, Kamila
    Cervenkova, Jana
    Schneiderova, Michaela
    Burocziova, Monika
    Burdova, Kamila
    Stranecky, Viktor
    Foretova, Lenka
    Machackova, Eva
    Tavandzis, Spiros
    Kmoch, Stanislav
    Macurek, Libor
    Kleibl, Zdenek
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (07) : 1782 - 1797
  • [49] Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations
    Foluso O. Ademuyiwa
    Patricia Salyer
    Yinjiao Ma
    Sherri Fisher
    Graham Colditz
    Katherine Weilbaecher
    Laura J. Bierut
    Breast Cancer Research and Treatment, 2019, 178 : 151 - 159
  • [50] Access disparities and underutilization of germline genetic testing in Chilean breast cancer patients
    Acevedo, Francisco
    Walbaum, Benjamin
    Camus, Mauricio
    Manzor, Manuel
    Muniz, Sabrina
    Medina, Lidia
    Petric, Militza
    Reyes, Paula
    Dominguez, Francisco
    Puschel, Klaus
    Merino, Tomas
    Bravo, M. Loreto
    Pinto, Mauricio P.
    Ibanez, Carolina
    Hughes, Kevin
    Sanchez, Cesar
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 199 (02) : 363 - 370